Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

EasyJet PLC ADR (ESYJY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.56 +0.05    +0.78%
19:12:00 - Closed. Currency in USD ( Disclaimer )
  • Volume: 1,608
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 6.56 - 6.63
Type:  Equity
Market:  United States
EasyJet ADR 6.56 +0.05 +0.78%

OTC:ESYJY Financials

 
This summary provides an overview of the most significant critical numbers from each of the EasyJet PLC ADR financial reports, including theEasyJet PLC ADR income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.

Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the OTC:ESYJY financials over time via breakdowns of their annual reports.

easyJet plc reported earnings results for the full year ended September 30, 2023. For the full year, the company reported revenue was GBP 8,171 million compared to GBP 5,769 million a year ago. Net income was GBP 324 million compared to net loss of GBP 169 million a year ago. Basic earnings per share from continuing operations was GBP 0.431 compared to basic loss per share from continuing operations of GBP 0.224 a year ago. Diluted earnings per share from continuing operations was GBP 0.427 compared to diluted loss per share from continuing operations of GBP 0.224 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ESYJY Income Statement & Profits

Gross margin TTM 32.24%
Operating margin TTM 5.73%
Net Profit margin TTM 3.97%
Return on Investment TTM 6.05%
 Total Revenue  Net Income
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Revenue 2741 2741 1344.5 1344.5
Gross Profit 1108.5 1108.5 208.5 208.5
Operating Income 430 430 -196 -196
Net Income 315.5 315.5 -153.5 -153.5

ESYJY Balance Sheet

Quick Ratio MRQ 0.73
Current Ratio MRQ 1
LT Debt to Equity MRQ 52.74%
Total Debt to Equity MRQ 104.2%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Total Assets 9841 9841 10541 10541
Total Liabilities 7054 7054 8620 8620
Total Equity 2787 2787 1921 1921

%ENGLISH_NAME% Latest Cash Flow Statement

Cash Flow/Share TTM 2.05
Revenue/Share TTM 10.82
Operating Cash Flow  7.02%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 291 291 484.5 484.5
Cash From Investing Activities -90.5 -90.5 -185.5 -185.5
Cash From Financing Activities -435 -435 -275 -275
Net Change in Cash -240 -240 -54.5 -54.5
* In Millions of GBP (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ESYJY Price Commentary

Write your thoughts about EasyJet PLC ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Puk Pups
Puk Pups Dec 02, 2021 16:29
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Australia’s Chief Medical Officer Paul Kelly also said in a recorded message that there wasn’t any indication that the Omicron variant was more deadly than other strains: “Of the over 300 cases that have now been diagnosed in many countries, they have all been very mild or in fact had no symptoms at all.”Merck noted that its molnupiravir antiviral pill should perform similarly against Omicron as against other existing variants.Drugmaker GlaxoSmithKline reported Thursday that in early testing, COVID-19 antibody treatment were effective against new mutations found in the variant, and that they were now conducting in vitro testing to confirm this further.Omicron would follow the historic pattern of viruses where less severe and more transmissible viruses crowd out severe variants, eventually making the disease more akin to a seasonal flu than a deadly pandemic.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email